

## COMPANY OVERVIEW

Xenetic Biosciences is a biopharmaceutical company focused on the acquisition, research and development of novel oncology therapeutics, including next-generation cellular immunotherapies for difficult to treat cancers, including B-cell Lymphomas, as well as improved biologic drugs. The Company recently announced its plans to acquire the XCART platform, a novel CAR T technology engineered to target patient- and tumor- specific neoantigens. The acquisition is subject to conditions typical for a transaction of this kind, including appropriate stockholder approvals, and is expected to close in the first half of 2019. The Company plans to initially apply the XCART technology to develop cell-based therapeutics for the treatment of B-cell Lymphomas. We believe our personalized T cell therapies have the potential to offer cancer patients substantial benefits over the existing standard of care and currently approved CAR T therapies.

Xenetic's Phase 2 oncology asset, XBIO-101 (sodium cridanimod), is a small-molecule investigational immunomodulator and interferon inducer which, in exploratory clinical studies, has also been shown to increase progesterone receptor (PrR) and estrogen receptor (ER) expression in certain tumor tissues. The Company plans to pursue collaborations with immuno-oncology (I-O) companies in which it would seek to use XBIO-101 in combination with approved or developmental I-O compounds such as checkpoint inhibitors.

Additionally, Xenetic's proprietary drug development platform, PolyXen™, enables next-generation biologic drugs by improving their half-life and other pharmacological properties. The Company has ongoing business development activities to explore partnerships utilizing its PolyXen delivery platform.

## RECENT NEWS

### [Xenetic Biosciences, Inc. Reports 2018 Year End Results and Provides Corporate Update](#)

Apr 1 2019, 7:30 AM EDT

### [Xenetic Biosciences Announces Pricing of \\$3.1 Million Registered Direct Offering](#)

Mar 5 2019, 9:27 AM EST

## STOCK OVERVIEW

Symbol	XBIO
Exchange	Nasdaq
Market Cap	16.29m
Last Price	\$1.56
52-Week Range	\$1.3691 - \$8.95

04/18/2019 04:00 PM EDT

## INVESTOR RELATIONS

Jenene Thomas Communications, LLC.  
Jenene Thomas  
T: 833-475-8247  
[xbio@jtcir.com](mailto:xbio@jtcir.com)

## MANAGEMENT TEAM

**Jeffrey F. Eisenberg**  
Chief Executive Officer

**Curtis Lockshin, Ph.D.**  
Chief Scientific Officer

**James F. Parslow**  
Chief Financial Officer

## XENETIC BIOSCIENCES, INC.

99 Hayden Avenue  
Suite 230  
Lexington, MA 02421  
US

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.